ToxiPharm LLC

ToxSignal

Clinical Toxicology Intelligence

Issue

#08

June 2026

DEA Opened Schedule III Hearings on June 29. Here Is What Changes for Your Testing Program.

The DEA's formal administrative law proceedings to move marijuana from Schedule I to Schedule III of the Controlled Substances Act opened June 29, 2026. The proposal stems from an HHS recommendation in August 2023 that cannabis meets Schedule III criteria. The hearing that opened today is the beginning of the legal record, not the end. No rescheduling has occurred, and the adjudicatory process could take months or longer to conclude.

Even if Schedule III classification is ultimately granted, the operational implications for UDT programs are more limited than the surrounding coverage suggests. Schedule III status would acknowledge that marijuana has some accepted medical use and a lower abuse potential relative to Schedule I and II substances. It would not federalize recreational use, nullify program-level prohibitions, or alter drug testing requirements for federally mandated programs. For DOT-regulated employers and federal agencies, marijuana would remain a tested and reportable analyte under a zero-tolerance standard. Drug court programs can continue to prohibit marijuana use regardless of federal scheduling status. OTP patients enrolled in methadone or buprenorphine programs are subject to program rules that operate independent of the CSA scheduling of marijuana.

The one area worth watching over the longer term: if Schedule III classification changes FDA regulatory pathways for cannabis-based medications or DEA research access rules, there may be downstream effects on testing panel development and interpretation guidance. Those changes would require separate rulemaking and would not be automatic.

U.S. Drug Enforcement Administration. Schedules of Controlled Substances: Rescheduling of Marijuana. Administrative hearing proceedings. June 2026.  ·  U.S. Department of Health and Human Services. HHS Recommendation on Marijuana Scheduling. August 2023.

Deadline: December 31, 2026

Buprenorphine Telemedicine Prescribing Flexibilities Expire at Year-End. The Transition Window Is Now.

The DEA's COVID-era flexibilities that allowed clinicians to initiate buprenorphine via telemedicine without a prior in-person evaluation are currently set to expire December 31, 2026. Providers who have been prescribing under these flexibilities should begin planning now for how their panel will transition before the deadline. Patients who have never had an in-person evaluation with their prescriber will need one scheduled before year-end, or a transfer to a provider who can complete that encounter.

Programs that expanded MOUD access by relying on telehealth initiation during the pandemic should audit their current panel for compliance exposure now. December has a way of arriving faster than it looks from June, and last-minute appointment scheduling for MOUD patients carries real clinical risk if continuity breaks down. An in-person visit requirement is not simply administrative: for many patients it is a barrier that took the flexibility waiver to eliminate in the first place.

If a permanent telemedicine prescribing rule is finalized before year-end, the landscape could change again. Watch for DEA rulemaking updates through the fall. In the meantime, plan for the sunset as if it is happening on schedule.

U.S. Drug Enforcement Administration. Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Extended through December 31, 2026. Federal Register.

PROVISIONAL SURVEILLANCE / CDC

Overdose Deaths Fell 13% Last Year. Here Is What Is Actually Driving the Decline.

The CDC's most recent provisional 12-month overdose surveillance data document 69,147 drug overdose deaths in the United States, a 13.2% decline from the comparable prior-year period. Synthetic opioid deaths (primarily fentanyl and its analogues) fell approximately 35.6%, the largest single-year decline recorded in the fentanyl era. Deaths involving stimulants also declined. The trend held across most regions and most demographic groups, though disparities by race and geography remain substantial.

The contributing factors are still being characterized and likely include expanded naloxone distribution, growth in MOUD access, and changes in illicit fentanyl supply composition. What the data do not fully resolve: whether the decline in synthetic opioid deaths is being partially offset by rising mortality involving xylazine, nitazenes, or other emerging adulterants that current surveillance infrastructure may not yet capture completely.

Centers for Disease Control and Prevention. Drug Overdose Surveillance and Epidemiology (DOSE) system. Provisional 12-month overdose death counts. 2026.  ·  CDC overdose data →